Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: REVATIO

« Back to Dashboard
Revatio is a drug marketed by Pfizer and is included in three NDAs. It is available from five suppliers.

The generic ingredient in REVATIO is sildenafil citrate. There are nineteen drug master file entries for this compound. Twelve suppliers are listed for this compound. There are ten tentative approvals for this compound. Additional details are available on the sildenafil citrate profile page.

Summary for Tradename: REVATIO

Suppliers / Packagers: see list11

Pharmacology for Tradename: REVATIO

Clinical Trials for: REVATIO

A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions
Status: Completed Condition: Pulmonary Arterial Hypertention

Sildenafil in Single Ventricle Patients
Status: Completed Condition: Heart Disease

Pharmacokinetics of Sildenafil in Premature Infants
Status: Recruiting Condition: Persistent Pulmonary Hypertension of the Newborn

Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
Status: Suspended Condition: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy

Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?
Status: Completed Condition: Pulmonary Hypertension

Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles
Status: Completed Condition: Endometrial Preparation; Frozen Embryo Transfer

Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Status: Recruiting Condition: Solid Tumor

Effects of Viagra on Heart Function in Patients With Heart Failure
Status: Completed Condition: Heart Failure; Left Ventricular Dysfunction

Sildenafil for Prevention of Cerebral Vasospasm
Status: Withdrawn Condition: Subarachnoid Hemorrhage; Cerebral Vasospasm; Rupture of Intracranial Aneurysm

VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension
Status: Completed Condition: Pulmonary Hypertension Associated With Connective Tissue Disease

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
sildenafil citrate
FOR SUSPENSION;ORAL203109-001Aug 30, 2012RXYes<disabled><disabled>
sildenafil citrate
SOLUTION;INTRAVENOUS022473-001Nov 18, 2009RXYes<disabled><disabled>
sildenafil citrate
FOR SUSPENSION;ORAL203109-001Aug 30, 2012RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn